Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
MariMed Inc. (CSE:MRMD) (OTCQX:MRMD) announced on Monday that it closed a $58.7 million secured credit facility with a U.S. chartered bank on Nov. 17, 2023.
See also: Rising Star Among Cannabis Companies: Why MariMed Deserves Your Attention
Jon Levine, MariMed’s CEO said the closing of the debt refinancing would “generate significant cash savings.”
The loan proceeds were used to pay off the existing term loans with Chicago Atlantic and Bank of New England and a seller's note from the Ermont acquisition, which in the aggregate totaled approximately $46.8 million.
“By paying off the Chicago Atlantic loan, we were also able to unencumber our operating assets in Illinois, Ohio, and Delaware, as well as our branded products, providing additional levers for future term loans at attractive rates if we choose,” Levine continued. “Additionally, the credit facility bolsters our ability to continue executing our strategic plan, particularly as it relates to growing the Company through mergers and acquisitions.”
The remaining funds will be held in escrow by the lender to complete the expansion of the company’s Hagerstown, Maryland cultivation facility.
Any unused proceeds will be released to the company after completion of the cultivation facility expansion.
“There are many attractive opportunities for accretive deals to be made in our industry, and we intend to explore any that will increase shareholder value,” Levine said.
MariMed’s shares traded 0.10% lower at $0.3096 per share at the time of writing on Monday morning.
Photo: Courtesy of geralt and Kindel Media by Pixabay